Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Trial of Antiestrogen Therapy Versus Combined Antiestrogen and Octreotide Therapy in the Adjuvant Treatment of Breast Cancer in Post-Menopausal Women

Next Previous
X
Search
Trial Profile

A Randomized Trial of Antiestrogen Therapy Versus Combined Antiestrogen and Octreotide Therapy in the Adjuvant Treatment of Breast Cancer in Post-Menopausal Women

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Octreotide (Primary) ; Tamoxifen
  • Indications Adenocarcinoma; Advanced breast cancer; Early breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 31 Mar 2017 Results (n=14729) assessing impact of baseline BMI and weight change on clinical outcomes with adjuvant breast cancer systemic therapy using data from six trials (chemotherapy trials-MA.5-NCI-V90-002 and MA.21-NCT00014222, endocrine therapy trials-MA.12-NCT00002542 and MA.14-NCT00002864, MA-27-NCT00066573 and trastuzumab trial-HERA, NCT00045032), published in the Annals of Oncology.
    • 05 Jun 2010 Results after a median follow-up of 9.8 years presented at ASCO 2010.
    • 02 Jul 2008 Results reported at ASCO 2008 (1112254).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top